Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

BOSTON - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported fourth-quarter revenue that exceeded analyst estimates, driving its stock up 0.8% in after-hours trading Monday. The biotechnology ...

SpotDraft, the CLM platform that helps in-house legal teams manage their contract ecosystems, has raised $54 million in ...

The combination will be made available immediately to qualifying patients in Germany, according to Vertex, and will be available shortly in the UK and other countries that have reimbursement ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis ... and we will not stop until everyone with CF across the UK has access to life-saving drugs.” ...

The S&P 500 Index ($SPX) (SPY) today is up +0.73%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.27%, and the Nasdaq ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

Real-time index price for Nasdaq Composite (NASX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

What does this have to do with the precious metals market? While this is not a direct reason for the precious metals market ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.